GS-9219
- CAS No.
- 859209-74-8
- Chemical Name:
- GS-9219
- Synonyms
- GS-9219;VDC-1101;Rabacfosadine;GS-9219 Rabacfosadine;L-Alanine, N,N'-[[[2-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]ethoxy]methyl]phosphinylidene]bis-, 1,1'-ethyl ester;Diethyl (2S,2'S)-2,2'-[[[[2-[2-Amino-6-(cyclopropylamino)-9H-purin-9-yl]ethoxy]methyl]phosphoryl]bis(azanediyl)]dipropanoate
- CBNumber:
- CB62668671
- Molecular Formula:
- C21H35N8O6P
- Molecular Weight:
- 526.53
- MDL Number:
- MFCD23704866
- MOL File:
- 859209-74-8.mol
- MSDS File:
- SDS
| Boiling point | 733.9±70.0 °C(Predicted) |
|---|---|
| Density | 1.50±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | Soluble in DMSO |
| pka | 4.81±0.10(Predicted) |
| form | Solid |
| color | Light yellow to yellow |
| FDA 21 CFR | 516.2065 |
| FDA UNII | M39BO43J9W |
GS-9219 Chemical Properties,Uses,Production
Uses
Rabacfosadine (GS-9219), a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.
in vivo
Rabacfosadine (RAB) has substantial single-agent activity in dogs with lymphoma, and a different mechanism of action than Doxorubicin (DOX). Open-label, multicenter prospective clinical trial. Dogs receive alternating Rabacfosadine (1.0 mg/kg IV weeks 0, 6, 12) and Doxorubicin (30 mg/m2 IV weeks 3, 9, 15). Dogs that achieved complete response (CR) are followed by monthly evaluations. Complete clinicopathological evaluation and assessment of remission and adverse event (AEs) are performed every 21 days. Acute AEs, occurring within 21 days after administration of the first dose of each agent, are compared between Rabacfosadine and Doxorubicin in 46 dogs receiving at least 1 dose of each agent[2].
References
[1] Reiser H, et al. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 1;14(9):2824-32. DOI:10.1158/1078-0432.CCR-07-2061
[2] Thamm DH, et al. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Na?ve Canine Multicentric Lymphoma. J Vet Intern Med. 2017 May;31(3):872-878. DOI:10.1111/jvim.14700
GS-9219 Preparation Products And Raw materials
Raw materials
Preparation Products
GS-9219 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +17819995354 | marketing@targetmol.com | United States | 32284 | 58 |
| NewCan Biotech Limited | +86-0571-86912261 +8613735419629 | sales@newcanbio.com | China | 9985 | 58 |
| MedChemexpress LLC | 021-58955995 | sales@medchemexpress.cn | United States | 4861 | 58 |
| Beijing xinyanhui pharmaceutical research and development co., LTD | 13969155946 | 1461866103@qq.com | China | 16111 | 58 |
| Wuhan Yingnuo Pharmaceutical Technology Co., Ltd. | +86-027-59232304 15387063101 | 2881924050@qq.com | China | 10026 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24892 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
| Shaoyuan Technology (Shanghai) Co., Ltd. | 021-50795510 4000665055 | sy-c6@accelachem.com | China | 10000 | 58 |
| RD International Technology Co., Limited | 18024082417 | market@ubiochem.com | China | 9835 | 58 |
| Olix (Shanghai) Pharmaceutical Technology Co., Ltd | 17316404525 | 209533805@qq.com | China | 9977 | 58 |
View Lastest Price from GS-9219 manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2025-06-05 | Rabacfosadine
859209-74-8
|
US $129.00-479.00 / mg | 99.43% | 10g | TargetMol Chemicals Inc. |
-
- Rabacfosadine
859209-74-8
- US $129.00-479.00 / mg
- 99.43%
- TargetMol Chemicals Inc.